GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » Equity-to-Asset

Nymox Pharmaceutical (Nymox Pharmaceutical) Equity-to-Asset : -2.84 (As of Sep. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Nymox Pharmaceutical's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-1.90 Mil. Nymox Pharmaceutical's Total Assets for the quarter that ended in Sep. 2023 was $0.67 Mil.

The historical rank and industry rank for Nymox Pharmaceutical's Equity-to-Asset or its related term are showing as below:

NYMXF' s Equity-to-Asset Range Over the Past 10 Years
Min: -10.62   Med: -0.61   Max: 0.87
Current: -2.84

During the past 13 years, the highest Equity to Asset Ratio of Nymox Pharmaceutical was 0.87. The lowest was -10.62. And the median was -0.61.

NYMXF's Equity-to-Asset is ranked worse than
95.14% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs NYMXF: -2.84

Nymox Pharmaceutical Equity-to-Asset Historical Data

The historical data trend for Nymox Pharmaceutical's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical Equity-to-Asset Chart

Nymox Pharmaceutical Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.87 0.63 0.49 -0.35 -0.30

Nymox Pharmaceutical Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 -0.30 -3.13 -10.62 -2.84

Competitive Comparison of Nymox Pharmaceutical's Equity-to-Asset

For the Biotechnology subindustry, Nymox Pharmaceutical's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nymox Pharmaceutical's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's Equity-to-Asset falls into.



Nymox Pharmaceutical Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Nymox Pharmaceutical's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )=Total Stockholders Equity/Total Assets
=-0.482/1.625
=

Nymox Pharmaceutical's Equity to Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

Equity to Asset (Q: Sep. 2023 )=Total Stockholders Equity/Total Assets
=-1.902/0.669
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nymox Pharmaceutical  (OTCPK:NYMXF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Nymox Pharmaceutical Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Executives
James George Robinson director 10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen officer: Chief Financial Officer 9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback director, 10 percent owner, officer: CEO C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham director, officer: General Counsel

Nymox Pharmaceutical (Nymox Pharmaceutical) Headlines

From GuruFocus

Nymox Announces Closing of $6.4 Million Financing

By GuruFocusNews GuruFocusNews 04-04-2022

NYMOX Appeals Deficiency Letter

By Stock market mentor Stock market mentor 01-06-2023

Nymox Provides Current Update

By sperokesalga sperokesalga 05-10-2023

Nymox Delisting from NASDAQ

By Marketwired 07-05-2023

NYMOX Update

By Marketwired 07-07-2023

NYMOX Presenting at Torrey Hills Capital Emerging Growth Conference

By GlobeNewswire GlobeNewswire 11-15-2021

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 05-23-2022

May 2023 Market Cap Requirement Update

By Value_Insider Value_Insider 11-25-2022

NYMOX Provides Shareholder Update

By Marketwired Marketwired 09-10-2021